Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors

References

• Rønholt K, Iversen L. Old and new biological therapies for psoriasis. IJMS. 2017;18(11):2297.
   Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983–994.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. Safety of biologics in psoriasis. J Dermatol. 2018;45(3):279–286.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Ly K, Smith MP, Thibodeaux Q, et al. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15(11):1185–1194.
   PubMed Web of Science ®Google Scholar
• Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;18(6):612–621.
   PubMed Web of Science ®Google Scholar
• Welch EZ, Anderson KL, Feldman SR. Interleukin 17 deficiency and implications in cutaneous and systemic diseases. J Dermatol Dermatol Surg. 2015;19(2):73–79.
   Google Scholar
• Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol. 2011;186(3):1666–1674.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62.
   PubMed Web of Science ®Google Scholar
• Wan MT, Shin DB, Winthrop KL, et al. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(2):677–679.
   PubMed Web of Science ®Google Scholar
• Schoot TS, Kerckhoffs APM, Hilbrands LB, et al. Immunosuppressive drugs and COVID-19: a review. Front Pharmacol. 2020;11:1333.
   PubMed Web of Science ®Google Scholar
• Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19 – a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Dreiher J, Regev-Rosenberg S, et al. The quality indigators program in Clalit Health Services: the first decade. Harefuah. 2010;149(4):204–209, 265.
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25–e25.
   Web of Science ®Google Scholar
• Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92(10):1915–1921.
   PubMed Web of Science ®Google Scholar
• Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020;20(2):124–127.
   PubMed Web of Science ®Google Scholar
• Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–272.
   PubMed Web of Science ®Google Scholar
• Ma WT, Yao XT, Peng Q, et al. The protective and pathogenic roles of IL-17 in viral infections: friend or foe? Open Biol. 2019;9(7):190109.
   PubMed Web of Science ®Google Scholar
• Crowe CR, Chen K, Pociask DA, et al. Critical role of IL-17RA in immunopathology of influenza infection. J Immunol. 2009;183(8):5301–5310.
   PubMed Web of Science ®Google Scholar
• Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–346.
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
   PubMed Web of Science ®Google Scholar
• Muir R, Osbourn M, Dubois AV, et al. Innate lymphoid cells are the predominant source of IL-17A during the early pathogenesis of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2016;193(4):407–416.
   PubMed Web of Science ®Google Scholar
• Xie M, Cheng B, Ding Y, et al. Correlations of IL-17 and NF-κB gene polymorphisms with susceptibility and prognosis in acute respiratory distress syndrome in a Chinese population. Biosci Rep. 2019;39(2):BSR20181987.
   PubMedGoogle Scholar
• Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19–related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management. Hear Rhythm. 2020;17(9):1463–1471.
   PubMed Web of Science ®Google Scholar
• Myers JM, Cooper LT, Kem DC, et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight. 2016;1(9):e85851.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang C, Huang F, et al. 2019-Novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury. ChinaXiv. [Internet]. 2020. Available from: http://www.chinaxiv.org/abs/202002.00018.
   Google Scholar
• Ayhan E, Öztürk M, An İ, et al. Potential role of anti-interleukin-17 in COVID-19 treatment. Dermatol Ther. 2020;33(4):e13715.
   PubMed Web of Science ®Google Scholar
• D’Adamio S, Silvaggio D, Lombardo P, et al. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Exp Opin Drug Saf. 2019;18(11):1031–1041.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology. 2020;59(12):3834–3844.
   PubMed Web of Science ®Google Scholar
• Balestri R, Rech G, Girardelli CR. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(8):e357–e358.
   PubMed Web of Science ®Google Scholar
• Foti R, Amato G, Elisa V. SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor. Med Hypotheses. 2020;144:110040.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Bombonato C, Motolese A. COVID-19 in an elderly patient treated with secukinumab. Dermatologic Therapy. 2020;33(4):e13580.
   PubMed Web of Science ®Google Scholar
• Haberman R, Axelrad J, Chen A, et al. Covid-19 in immune-mediated inflammatory diseases – case series from New York. N Engl J Med. 2020;383(1):85–88.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Tofani L, Bianchi L, et al. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Exp Opin Biol Ther. 2020;20(8):829–830.
   PubMed Web of Science ®Google Scholar
• Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481–491.e3.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Orlando A. COVID-19 in patients with inflammatory bowel disease: a systematic review of clinical data. Dig Liver Dis. 2020;52(11):1222–1227.
   PubMedGoogle Scholar
• Gianfrancesco M, Hyrich KL, Hyrich KL, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866.
   PubMed Web of Science ®Google Scholar
• Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatol Treat. 2020;31(4):317–318.
   PubMed Web of Science ®Google Scholar
• Tao J, Song Z, Yang L, et al. Emergency management for preventing and controlling nosocomial infection of the 2019 novel coronavirus: implications for the dermatology department. Br J Dermatol. 2020;182(6):1477–1478.
   PubMed Web of Science ®Google Scholar